Cambridge, UK, 21 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with CCL, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK, Ireland (non-exclusive), the Middle East and the Balkans (exclusively).
Under the agreement, Cambridge based CCL will manage and facilitate the fulfilment of orders of PredictSURE IBD™, as well as receive and process all samples.…
Cambridge, UK, 21 January 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative drugs and diagnostics. Financial details of the agreement are not disclosed.
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease relevant pathways nominated by Otsuka. Novel targets…
Cambridge, UK., 16 January 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA on 20-24 January 2020.
Dr. Jezek’s PEPTalk presentation, entitled ‘Controlling Aggregation of a Range of Novel Biopharmaceutical Product Modalities’, will summarise several case studies demonstrating the capability of Arecor’s formulation technology platform, Arestat™, to develop differentiated biopharmaceutical…
Cambridge, UK, 14 January 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications. This technology is incorporated into Horizon’s next-generation gene editing platform to enable the development of novel therapeutics that rely on engineering patient’s cells either directly…
Cambridge, UK, - 15 January 2020 – Abcam plc, a global leader in the supply of life science research tools, announced the appointment of Michael Baldock as Chief Financial Officer (CFO) and Board member with effect from 3 February 2020.
Michael has over 30 years of corporate and financial experience gained through senior leadership roles at HSBC, Lazard, Bentley Health Care and SG Warburg. He is a founding partner at Ondra Partners, an independent financial advisory firm which has advised Abcam for several years.
The Board believe that his experience, deep sector expertise and knowledge…
Cambridge, UK, 13 January 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Group”), a global leader in the application of gene editing and gene modulation technologies, has announced that it has signed a collaboration and license agreement with Mammoth Biosciences (“Mammoth” or the “Company”), to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies.
Horizon’s Bioproduction business unit currently offers the biopharmaceutical…
CAMBRIDGE, UK, and LEUVEN, Belgium, 13 January 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec, a world-leading research and innovation hub active in the fields of nanoelectronics and digital technologies, to increase production of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale. The novel silicon chip is a key component of Evonetix’s desktop DNA platform…
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
Product designed to provide safer, more immediate treatment option for patients
London and Cambridge, January 9, 2020 - Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-…
08 January 2020, London, UK: Optimum Strategic Communications (Optimum), the international strategic healthcare communications firm, today announced the appointment of Shabnam Bashir. Shabnam brings 10 years of experience advising UK and international companies ranging from start-ups to large public organisations across a range of sectors advising on strategy, crises management, IPO and M&A transactions.
Shabnam joins from Citigate Dewe Rogerson (part of Huntsworth Health), where she applied her broad-based experience to support the Life sciences and Healthcare team. In her role at…
J A Kemp LLP has appointed Dr Ian MacLeod as a Partner in its London office.
Ian is qualified as a European and UK Chartered Patent Attorney. He joined J A Kemp in January 2020 after working for over ten years at another top tier firm. [Carpmaels & Ransford]
Ian handles a wide range of subject matter in the biotechnological and life sciences field, with particular expertise in bacterial products targeting the microbiome, vaccines, antibody therapeutics, biomarker diagnostics, and antisense nucleotides.
Ian has extensive experience of drafting patents and of prosecuting and defending…